[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR100725263B1 - ＨＭＧ-ＣｏＡ 리덕타제 억제제 및 카르니틴을 포함하는 항지질혈성 복합제 - Google Patents

ＨＭＧ-ＣｏＡ 리덕타제 억제제 및 카르니틴을 포함하는 항지질혈성 복합제 Download PDF

Info

Publication number
KR100725263B1
KR100725263B1 KR1020017015675A KR20017015675A KR100725263B1 KR 100725263 B1 KR100725263 B1 KR 100725263B1 KR 1020017015675 A KR1020017015675 A KR 1020017015675A KR 20017015675 A KR20017015675 A KR 20017015675A KR 100725263 B1 KR100725263 B1 KR 100725263B1
Authority
KR
South Korea
Prior art keywords
carnitine
pharmaceutical composition
acid
delete delete
alkanoyl
Prior art date
Application number
KR1020017015675A
Other languages
English (en)
Korean (ko)
Other versions
KR20020025066A (ko
Inventor
아르두이니아르두이노
페스체체라알레싼드로
카르미나티파올로
Original Assignee
시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99830415A external-priority patent/EP1064943B1/fr
Application filed by 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. filed Critical 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Publication of KR20020025066A publication Critical patent/KR20020025066A/ko
Application granted granted Critical
Publication of KR100725263B1 publication Critical patent/KR100725263B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020017015675A 1999-06-08 2000-06-05 ＨＭＧ-ＣｏＡ 리덕타제 억제제 및 카르니틴을 포함하는 항지질혈성 복합제 KR100725263B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13800899P 1999-06-08 1999-06-08
US60/138,008 1999-06-08
EP99830415.8 1999-06-30
EP99830415A EP1064943B1 (fr) 1999-06-30 1999-06-30 Combinaison ayant une activité hypolipémiante substantiellement dénuée des effets toxiques ou effets secondaires causés par les médicaments à activité hypolipémiante

Publications (2)

Publication Number Publication Date
KR20020025066A KR20020025066A (ko) 2002-04-03
KR100725263B1 true KR100725263B1 (ko) 2007-06-07

Family

ID=26153794

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017015675A KR100725263B1 (ko) 1999-06-08 2000-06-05 ＨＭＧ-ＣｏＡ 리덕타제 억제제 및 카르니틴을 포함하는 항지질혈성 복합제

Country Status (10)

Country Link
JP (1) JP2003501385A (fr)
KR (1) KR100725263B1 (fr)
AU (1) AU782188B2 (fr)
CA (1) CA2375378C (fr)
CZ (1) CZ20014218A3 (fr)
HU (1) HUP0201597A3 (fr)
MX (1) MXPA01012644A (fr)
PL (1) PL197899B1 (fr)
SK (1) SK285900B6 (fr)
WO (1) WO2000074675A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100029759A1 (en) * 2007-02-27 2010-02-04 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition useful for the treatment of type 2 diabetes
SI2136798T1 (sl) * 2007-03-21 2015-10-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Sestavek, uporaben za preprečevanje diabetesa tipa 2 in njegovih komplikacij pri preddiabetičnih bolnikih z inzulinsko rezistenco
US20110052556A1 (en) * 2008-02-29 2011-03-03 Biolab Sanus Farmaceutical Ltda Pharmaceutical composition comprising racetam and carnitine and process for its preparation
US20120130202A1 (en) * 2010-11-24 2012-05-24 Fujitsu Limited Diagnosis and Monitoring of Musculoskeletal Pathologies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001126A1 (fr) * 1997-07-01 1999-01-14 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compositions pharmaceutiques comprenant alcanoyle l-carnitine en combinaison avec une statine pour traiter des pathologies resultant d'un metabolisme lipidique altere

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0667833B2 (ja) * 1985-11-28 1994-08-31 雪印乳業株式会社 経腸栄養剤
DE69001146T2 (de) * 1989-01-18 1993-10-07 Merck & Co Inc Koenzym Q10 mit HMG-COA-Reduktase-Inhibitoren.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001126A1 (fr) * 1997-07-01 1999-01-14 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compositions pharmaceutiques comprenant alcanoyle l-carnitine en combinaison avec une statine pour traiter des pathologies resultant d'un metabolisme lipidique altere

Also Published As

Publication number Publication date
SK17152001A3 (sk) 2002-03-05
MXPA01012644A (es) 2002-07-22
AU782188B2 (en) 2005-07-07
WO2000074675A1 (fr) 2000-12-14
HUP0201597A2 (en) 2002-09-28
AU5969700A (en) 2000-12-28
PL197899B1 (pl) 2008-05-30
SK285900B6 (sk) 2007-10-04
KR20020025066A (ko) 2002-04-03
PL352106A1 (en) 2003-07-28
JP2003501385A (ja) 2003-01-14
CZ20014218A3 (cs) 2002-04-17
CA2375378C (fr) 2009-08-11
CA2375378A1 (fr) 2000-12-14
HUP0201597A3 (en) 2003-04-28

Similar Documents

Publication Publication Date Title
US5053429A (en) Treating inflammatory pain with methionine
JPH09176004A (ja) 脂質代謝障害から引き起こされる疾患の予防および処置のためのｌ−カルニチンまたはアルカノイル ｌ−カルニチン含有医薬組成物
PT2704734E (pt) Composição útil para o tratamento de distúrbios do metabolismo de lípidos
US11911382B2 (en) Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
US6245800B1 (en) Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine
US9642860B2 (en) Combinations of corroles and statins
AU726822B2 (en) Pharmaceutical compositions comprising alkanoyl L-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism
KR100725263B1 (ko) ＨＭＧ-ＣｏＡ 리덕타제 억제제 및 카르니틴을 포함하는 항지질혈성 복합제
EP1064943B1 (fr) Combinaison ayant une activité hypolipémiante substantiellement dénuée des effets toxiques ou effets secondaires causés par les médicaments à activité hypolipémiante
CN113134086B (zh) 一种降血脂的药物组合物
US20050182036A1 (en) Medicinal composition containing an HMG-CoA reductase inhibitor
CA2678746C (fr) Composition a utiliser pour le traitement du diabete de type 2
MXPA99011665A (en) Pharmaceutical compositions comprising alkanoyl l-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism
CN1332657C (zh) 一种含洛伐他汀的组合物及其用途

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]
FPAY Annual fee payment

Payment date: 20130509

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20140514

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20150512

Year of fee payment: 9

LAPS Lapse due to unpaid annual fee